Krystal Biotech, Inc.
KRYS · XNASCIK 1711279fmd_0FRNPSBSEAGBK30C098WA3X6VBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 42 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 51 | 291 | 389 |
| Realized investment gains (losses) | – | – | – | – | – | 0 | 1 | 5 | 6 | 6 |
| Research and development | 1 | 3 | 8 | 16 | 18 | 28 | 42 | 46 | 54 | 58 |
| Selling, general and administrative | – | – | – | – | – | – | 78 | 98 | 114 | 147 |
| Total operating expenses | 1 | 5 | 12 | 22 | 33 | 68 | 145 | 160 | 225 | 228 |
| Operating income | (1) | (5) | (12) | (22) | (33) | (68) | (145) | (110) | 66 | 161 |
| Interest expense | – | – | – | – | 0 | 1 | 0 | 0 | – | – |
| Other non-operating income (expense) | (0) | (3) | – | – | – | – | – | – | – | – |
| Income before taxes | – | – | – | – | – | (70) | (140) | 13 | 95 | 189 |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | (15) |
| Net income from continuing operations | – | – | – | – | – | (70) | (140) | 11 | 89 | 205 |
| Net income | (1) | (8) | (11) | (19) | (32) | (70) | (140) | 11 | 89 | 205 |
| Net income to common shareholders | (1) | (8) | – | – | – | – | – | – | – | – |